ClinicalTrials.gg
CompletedNCT05288660Updated May 9, 2023Results posted

A Study of a Single Dose of ALXN1210 in Healthy Participants

A Phase 1 interventional study of ALXN1210 and Placebo in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 years 6 months after the study started (first participant enrolled Aug 2014, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

This study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of ALXN1210 in healthy participants, as assessed by electrocardiograms, physical examination, vital signs, laboratory analysis, and assessment of adverse events (AEs).

Read the detailed description

The participants were randomized in a 2:1 ratio (4 active and 2 placebo) to receive a single dose of ALXN1210 or placebo in the 200-milligram (mg) dose cohort and in a 3:1 ratio (6 active and 2 placebo) to receive a single dose of ALXN1210 or placebo in the 400-mg dose cohort, administered by intravenous (IV) infusion. A 150-day observation period was performed for safety, pharmacokinetic, and pharmacodynamic assessments after study drug administration. Antidrug antibody (ADA) levels were monitored in study participants for the duration of the 150-day follow-up period.

02

Conditions studied

  • Healthy

Keywords

  • ALXN1210
  • Pharmacokinetic
  • Pharmacodynamic
  • Safety
  • Immunogenicity
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • from 18 through 29.9 kilogram (kg)/square meter, inclusive, and weight between 50 and 100 kg, inclusive.
  • (Fridericia's correction); ≤450 milliseconds (msec) for males and ≤470 msec for females at screening and pre-dose on Day 1.
  • Willing and able to give written and comply with the study visit schedule.
  • Male participant and his female spouse/partner who was of must be using highly effective consisting of 2 forms of birth control (at least 1 of which must be a barrier method), starting at screening and continuing until at least 5 months after the last dose of ALXN1210.
  • Documented vaccination with meningococcal conjugate vaccine (MCV4) at least 14 days and not more than 3 years prior to dosing.

Exclusion criteria

Exclusion Criteria:

  • Participants in intimate and prolonged contact (defined as living under the same roof or providing personal care) with individuals who are either , or with a specific underlying medical conditions (anatomic or functional asplenia [including sickle cell disease]; congenital complement, properdin, factor D, or primary antibody deficiencies; acquired complement deficiencies [for example, those receiving eculizumab]; and [HIV]), people younger than 2 years old and older than 65 years old, and professionals exposed to environments of greater risk for meningococcal disease (research, industrial, and clinical laboratory personnel who are routinely exposed to Neisseria meningitidis, military personnel during recruit training [military personnel may be at increased risk when accommodated in close quarters], daycare center workers, or those living on a college or university campus).
  • Participants living or working in the Saguenay-Lac-St-Jean area (due to increased incidence of meningococcal infections in that specific area).
  • Female participants of , including any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or who was pregnant, breastfeeding, or was not .
  • Positive serum pregnancy test at screening or Day -1.
  • Serum creatinine greater than the (ULN) of the testing laboratory at screening and Day -1.
  • or aspartate aminotransferase >ULN of the testing laboratory at screening and Day -1.
  • Any of the following hematology tests: \<135 grams (g)/L for males and \<120 g/L for females; hematocrit \<0.41 L/L for males and \<0.36 L/L for females; white blood cells \<3.5*10\^3/microliter (μL) or >ULN of the testing laboratory; absolute neutrophils \<1.5*10\^3/μL (\<1.0*10\^3/μL for black race volunteers) or >ULN of the testing laboratory; and \<the lower limit of normal of the testing laboratory or >450*10\^3/μL at screening and Day -1.
  • HIV infection (evidenced by HIV-1 or HIV-2 antibody titer).
  • Acute or chronic virus (HBV) infection (evidenced by the presence of HBV surface antigen or immunoglobulin M antibodies against HBV core antigen).
  • Acute or chronic virus infection (evidenced by antibody titer).
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing.
  • Positive QuantiFERON-TB test, indicating possible tuberculosis (TB) infection.
  • History of complement deficiency.
  • History of other than basal cell carcinoma.
  • Participated in a clinical trial within 30 days before initiation of dosing on Day 1, or used any experimental small-molecule therapy within 30 days prior to dosing on Day 1, or biologic therapy within 90 days prior to initiation of dosing on Day 1 or within 5 half-lives of the product, whichever is greater.
  • Major surgery within the last 90 days prior to dosing.
  • History of any Neisseria infection; history of unexplained, recurrent infection; or infection requiring treatment with systemic antibiotics within the last 90 days prior to dosing.
  • to receiving MCV4, including severe (life-threatening) allergic reaction to a previous dose of MCV4; severe (life-threatening) allergy to any vaccine component; previous diagnosis of Guillain-Barré Syndrome.
  • History of allergy to of ALXN1210 (that is, polysorbate 80)
  • History of allergy to penicillin or cephalosporin, or history of significant allergic reaction to other products (anaphylaxis and angioedema).
  • Positive urine drug toxicology screen.
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood of more than 50 mL of blood within 30 days of dosing, or more than 499 mL of blood within 56 days of dosing.
  • Clinical diagnosis of any or rheumatologic disease (for example, systemic lupus erythematosus, and rheumatoid arthritis) or other condition or medical history that, in the opinion of the Investigator, might interfere with the participant's participation in the study, poses an added risk for the participant, or confounds the assessment of the participant or outcome of the study.
  • History of latent or active TB or exposure to endemic areas within 8 weeks prior to the TB test performed at screening.
  • Immunization with a 1 month prior to dosing or planned vaccination during the course of the study (except for the vaccination planned by the study protocol).
  • Presence of fever (body temperature > 37.6°C) (for example, a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to the first dosing.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    ALXN1210 200 mg

    ALXN1210 was administered intravenously.

    Drug: ALXN1210

  • Experimental
    ALXN1210 400 mg

    ALXN1210 was administered intravenously.

    Drug: ALXN1210

  • Placebo comparator
    Placebo

    Placebo was administered intravenously.

    Drug: Placebo

Interventions

  • All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.

    Also known as: Ultomiris, Ravulizumab

  • DrugPlacebo

    All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Day 150

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of ALXN1210

    Blood samples were collected for estimation of Cmax by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  2. Time To Maximum Observed Serum Concentration (Tmax) of ALXN1210

    Blood samples were collected for estimation of Tmax by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  3. Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of ALXN1210

    Blood samples were collected for estimation of AUC0-t by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  4. Area Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of ALXN1210

    Blood samples were collected for estimation of AUCinf by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  5. Terminal Elimination Rate Constant (λz) of Serum ALXN1210

    Blood samples were collected for estimation of λz by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  6. Terminal Elimination Half-life (t½) of Serum ALXN1210

    Blood samples were collected for estimation of t½ by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  7. Total Clearance (CL) of ALXN1210

    Blood samples were collected for estimation of CL by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  8. Volume of Distribution (Vd) of ALXN1210

    Blood samples were collected for estimation of Vd by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

    Time frame: Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150

  9. Percent Change From Baseline in Free Complement Component 5 (C5)

    Blood samples were collected for analysis of free C5 concentrations.

    Time frame: Baseline, Day 150

  10. Percent Change From Baseline in Total Complement C5

    Blood samples were collected for analysis of total C5 concentrations.

    Time frame: Baseline, Day 150

  11. Percent Change From Baseline in Complement C5b-9

    Blood samples were collected for analysis of C5b-9 concentrations.

    Time frame: Baseline, Day 8

  12. Percent Change From Baseline in Chicken Red Blood Cell Hemolysis

    Blood samples were collected for analysis of cRBC hemolysis.

    Time frame: Baseline, Day 150

  13. Percent Change From Baseline In Complement Classical Pathway (CCP) Activity

    Blood samples were collected for analysis of CCP.

    Time frame: Baseline, Day 150

  14. Percent Change From Baseline In Complement Alternative Pathway (CAP) Activity

    Blood samples were collected for analysis of CAP.

    Time frame: Baseline, Day 150

  15. Percentage of Participants With Positive Anti-Drug Antibody (ADA)

    Blood samples were collected to evaluate antibody response through development of ADAs.

    Time frame: Baseline up to Day 150

07

Results

Posted May 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Started464
Received at least 1 dose of study drug464
Completed464
Not completed000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline up to Day 150
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)344
SecondaryMaximum Observed Serum Concentration (Cmax) of ALXN1210

Blood samples were collected for estimation of Cmax by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · microgram/milliliter (µg/mL)
Maximum Observed Serum Concentration (Cmax) of ALXN1210
microgram/milliliter (µg/mL)Cohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Maximum Observed Serum Concentration (Cmax) of ALXN121078.8 ± 8.02141 ± 23.9
SecondaryTime To Maximum Observed Serum Concentration (Tmax) of ALXN1210

Blood samples were collected for estimation of Tmax by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Median · hours
Time To Maximum Observed Serum Concentration (Tmax) of ALXN1210
hoursCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Time To Maximum Observed Serum Concentration (Tmax) of ALXN12102.44 (0.800 to 4.248)0.657 (0.594 to 1.161)
SecondaryArea Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of ALXN1210

Blood samples were collected for estimation of AUC0-t by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · microgram*hour/milliliter (µg*hr/mL)
Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of ALXN1210
microgram*hour/milliliter (µg*hr/mL)Cohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Area Under The Serum Concentration Versus Time Curve From Time Zero To The Time of The Last Quantifiable Concentration (AUC0-t) of ALXN121045400 ± 524078900 ± 16300
SecondaryArea Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of ALXN1210

Blood samples were collected for estimation of AUCinf by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · µg*hr/mL
Area Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of ALXN1210
µg*hr/mLCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Area Under The Serum Concentration Versus Time Curve From Time Zero (Dosing) To Infinity (AUCinf) of ALXN121047600 ± 622081900 ± 17800
SecondaryTerminal Elimination Rate Constant (λz) of Serum ALXN1210

Blood samples were collected for estimation of λz by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · 1/hour
Terminal Elimination Rate Constant (λz) of Serum ALXN1210
1/hourCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Terminal Elimination Rate Constant (λz) of Serum ALXN12100.000900 ± 0.0001460.000943 ± 0.0000934
SecondaryTerminal Elimination Half-life (t½) of Serum ALXN1210

Blood samples were collected for estimation of t½ by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · days
Terminal Elimination Half-life (t½) of Serum ALXN1210
daysCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Terminal Elimination Half-life (t½) of Serum ALXN121032.7 ± 5.1830.9 ± 3.20
SecondaryTotal Clearance (CL) of ALXN1210

Blood samples were collected for estimation of CL by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · milliliter/hour
Total Clearance (CL) of ALXN1210
milliliter/hourCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Total Clearance (CL) of ALXN12104.26 ± 0.6205.06 ± 0.990
SecondaryVolume of Distribution (Vd) of ALXN1210

Blood samples were collected for estimation of Vd by noncompartmental analyses using Pharsight Knowledgebase Server 4.0.2 and Phoenix WinNonlin 5.3.

Time frame:
Predose, 30 minutes, 4, 8, 24, 48, 96 hours postdose, then at Days 8, 15, 22, 29, 36, 43, 50, 57, 71, 90, 120 and 150
Reported as:
Mean · milliliters
Volume of Distribution (Vd) of ALXN1210
millilitersCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Volume of Distribution (Vd) of ALXN12104760 ± 4265340 ± 727
SecondaryPercent Change From Baseline in Free Complement Component 5 (C5)

Blood samples were collected for analysis of free C5 concentrations.

Time frame:
Baseline, Day 150
Reported as:
Mean · percent change
Percent Change From Baseline in Free Complement Component 5 (C5)
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline in Free Complement Component 5 (C5)4.76 ± 5.5219.88 ± 12.9924.46 ± 31.63
SecondaryPercent Change From Baseline in Total Complement C5

Blood samples were collected for analysis of total C5 concentrations.

Time frame:
Baseline, Day 150
Reported as:
Mean · percent change
Percent Change From Baseline in Total Complement C5
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline in Total Complement C531.02 ± 8.3423.39 ± 10.4615.33 ± 17.86
SecondaryPercent Change From Baseline in Complement C5b-9

Blood samples were collected for analysis of C5b-9 concentrations.

Time frame:
Baseline, Day 8
Reported as:
Mean · percent change
Percent Change From Baseline in Complement C5b-9
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline in Complement C5b-9-28.22 ± 19.11-40.73 ± 10.9234.68 ± 14.61
SecondaryPercent Change From Baseline in Chicken Red Blood Cell Hemolysis

Blood samples were collected for analysis of cRBC hemolysis.

Time frame:
Baseline, Day 150
Reported as:
Mean · percent change
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline in Chicken Red Blood Cell Hemolysis9.86 ± 7.5715.30 ± 29.35-4.68 ± 4.76
SecondaryPercent Change From Baseline In Complement Classical Pathway (CCP) Activity

Blood samples were collected for analysis of CCP.

Time frame:
Baseline, Day 150
Reported as:
Mean · percent change
Percent Change From Baseline In Complement Classical Pathway (CCP) Activity
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline In Complement Classical Pathway (CCP) Activity-13.16 ± 13.655.34 ± 6.05-1.81 ± 10.95
SecondaryPercent Change From Baseline In Complement Alternative Pathway (CAP) Activity

Blood samples were collected for analysis of CAP.

Time frame:
Baseline, Day 150
Reported as:
Mean · percent change
Percent Change From Baseline In Complement Alternative Pathway (CAP) Activity
percent changeCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mgPlacebo
Percent Change From Baseline In Complement Alternative Pathway (CAP) Activity-23.61 ± 19.91-24.66 ± 18.48-22.08 ± 13.18
SecondaryPercentage of Participants With Positive Anti-Drug Antibody (ADA)

Blood samples were collected to evaluate antibody response through development of ADAs.

Time frame:
Baseline up to Day 150
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-Drug Antibody (ADA)
percentage of participantsCohort 1: ALXN1210 200 mgCohort 2: ALXN1210 400 mg
Percentage of Participants With Positive Anti-Drug Antibody (ADA)00

Adverse events

Collected over Baseline up to Day 150. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALXN1210 200 mg0/4 (0%)1/4 (25%)3/4 (75%)
ALXN1210 400 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventALXN1210 200 mgALXN1210 400 mgPlacebo
Myocardial InfarctionCardiac disorders1/40/60/4
Most frequent other events
Showing 10 of 36
Most frequent other events
EventALXN1210 200 mgALXN1210 400 mgPlacebo
HeadacheNervous system disorders0/43/63/4
NasopharyngitisInfections and infestations0/41/62/4
Back PainMusculoskeletal and connective tissue disorders0/40/62/4
PresyncopeNervous system disorders0/40/61/4
Infusion Site PainGeneral disorders1/41/61/4
AstheniaGeneral disorders0/40/61/4
Chest PainGeneral disorders1/40/60/4
ChillsGeneral disorders0/40/61/4
Feeling HotGeneral disorders0/40/61/4
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders0/41/61/4

Baseline characteristics

The safety population was defined as the group of participants who received any dose of the study drug (ALXN1210 or placebo).

Age, Continuous
Age, Continuous(years)ALXN1210 200 mgALXN1210 400 mgPlaceboTotal
Mean44.0 ± 9.4241.8 ± 8.3346.3 ± 8.3443.7 ± 8.18
Sex: Female, Male
Sex: Female, Male(Participants)ALXN1210 200 mgALXN1210 400 mgPlaceboTotal
Female2327
Male2327
08

Study locations

1 site
  • Clinical Trial Site
    Montréal, Canada
09

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Clinical study report

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Mar 2015, 6 months.

Results were first posted in May 2023, 8 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2022
First posted
Mar 21, 2022
StartActual
Aug 27, 2014
Primary completionActual
Mar 13, 2015
CompletionActual
Mar 13, 2015
Results first posted
May 9, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05288660
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Aug 27, 2014
Primary completion
Mar 13, 2015
Completion
Mar 13, 2015
Results posted
May 9, 2023
Last update
May 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion